Cryoport and Zoetis Expand Cold Chain Logistics Relationship

LAKE FOREST, Calif.--(BUSINESS WIRE)-- Cryoport, Inc. (OTCBB: CYRX) today announced that it has reached agreement with Zoetis Inc. (formerly the animal health business unit of Pfizer Inc.) to expand the scope of the cold chain logistics services Cryoport is providing.

In December 2012, Cryoport signed an agreement with Pfizer Inc. relating to Zoetis Inc. pursuant to which we were engaged to manage frozen shipments of a key poultry vaccine. Under this arrangement, Cryoport is providing on-site logistics personnel and its logistics management platform, the CryoportalTM, to manage shipments from the Zoetis manufacturing site in the United States to domestic customers as well as selected international distribution centers. As part of its logistics management services, Cryoport analyzes shipping data and processes to further streamline Zoetis' logistics, ensuring products arrive to their destinations in specified conditions, on-time and with the optimum uses of resources. Initially, Cryoport managed Pfizer’s total fleet of dewar flask shippers used for this purpose, including liquid nitrogen shippers.

In the amended agreement, Cryoport’s scope is expanded to manage all domestic shipments of the key frozen poultry vaccine as well as all shipments of this vaccine to all Zoetis’ international distribution centers.

Cryoport President and CEO Jerrell Shelton stated, “The solutions we provide Zoetis are made possible by our purpose-built Cryoportal software logistics management system and our 24/7 logistics personnel who power the solutions we provide. By outsourcing cold chain logistics to Cryoport, our customers can achieve reliable services and have greater visibility on the status of their shipments of vaccines throughout the entire delivery and return processes. Cryoport solutions provide greater peace of mind to our customers, knowing that our Cryoport solutions are not only reliable, but effective, and economically sound.”

About Cryoport, Inc.

Cryoport provides leading edge frozen shipping logistics solutions to the biotechnology and life science industries through the combination of purpose built proprietary hardware and software technologies and total turnkey management of the entire logistics process. Cryoport Express® liquid nitrogen dry vapor shippers are validated to maintain a constant -150°C temperature for a 10 plus day dynamic shipment duration, and its Cryoportal™ Logistics Management Platform manages the entire shipment process, including initial order input, document preparation, customs clearance, courier management, shipment tracking, issue resolution, and delivery. Cryoport’s total turnkey logistics solutions offer reliability, cost effectiveness, and convenience, while the use of recyclable and reusable components provides a “green” and environmentally friendly solution. Cryoport service options include recording the “chain of condition” and “chain of custody” for all shipments thereby meeting the exacting requirements for scientific work and for regulatory purposes. For more information visit

Forward Looking Statements

Statements in this press release which are not purely historical, including statements regarding Cryoport, Inc.’s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, and technical development risks. The company’s business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended March 31, 2013. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Cryoport, Inc.
Robert Stefanovich, 619-481-6802

Source: Cryoport, Inc.